Clinical Trial

Radiotherapy Combined With Endostatin and Capecitabine for NPC

Name: Radiotherapy Combined With Endostatin and Capecitabine for NPC — clinical trial record (NCT05514275)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Record status

This record was last updated August 24, 2022 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.

Trial Details

NCT Number	NCT05514275
Lead Sponsor	Zhejiang Cancer Hospital
Conditions	Nasopharyngeal Carcinoma
Enrollment	41 participants
Start Date	2022-08-01
Primary Completion	2026-08-01 (estimated)
Study Completion	2028-08-01 (estimated)
Updated on ClinicalTrials.gov	2022-08-24